

[REDACTED]
vendredi 9 juin 2017 09:43
[REDACTED]

In order to make your (& the contractor's) life easier, I have a name for Prescire of an expert who could be interviewed on the clinical value of orphans but the interview can take place in French only (unless it is a written survey/questionnaire). I hope there is still time for him to be included in the roster of possible interviewees. His name is [REDACTED] and he is Prescire's [REDACTED]. Here is his email address: [REDACTED] If/when the contractor contacts him it is best to put his colleague [REDACTED] [REDACTED] in copy: [REDACTED]

11



End Date: N/A
Billing Method: Free group plan with a health premium.
Social Security Number: Not applicable as it is not an employer-sponsored plan.
Eligible Dependents: None.
Plan Details: The plan provides comprehensive medical coverage, including hospitalization, surgery, and prescription drugs. It also includes dental and vision benefits. The cost of the plan is shared between the employee and the employer.

Dear [REDACTED],

1

Regarding the timing for the interview, we do not have the precise dates yet but indeed it is likely to be before the summer. I will keep you informed as soon as we received the revised methodology from the consultant.

Best regards,

[REDACTED]

From: [REDACTED]

Sent: Tuesday, May 30, 2017 4:03 PM

To: [REDACTED]

Cc: [REDACTED]

Subject: Re: Update on study

Dear all,

Here are a few suggestions. Problems with exclusivities & orphan drugs:


- 1) [REDACTED] of Harvard
- 2) [REDACTED] of Public Citizen [REDACTED]
- 3) [REDACTED] University of Michigan, [REDACTED]
- 4) [REDACTED] Centre for Health Economics & Medicines Evaluation | Bangor University- [REDACTED]
[REDACTED]
- 5) [REDACTED] of KEI on the role of exclusivities [REDACTED]
- 6) [REDACTED] | Medicines Law & Policy, [REDACTED]

Also, the contractor should contact Prescire to get articles on the clinical quality/innovative value of orphans. Prescire's articles are not relevant for the economic/IP analysis but they must be certainly consulted when it comes to assessing the questionable therapeutic value of orphan drugs, an issue within the mandate of this study. People from the Cochrane Collaboration can contribute with data too but I believe Prescire should do. I am at your disposal for any additional information.

If I recall correctly, you mentioned that whoever is interviewed will be contacted in/by July, is that still the case?

Thank you very much once again for all your hard & excellent work on this dossier!

[REDACTED]



[REDACTED]

European Public Health Alliance (EPHA) www.ephah.org



Rue de Trèves 49-51 1040 Brussels (B) | Transparency Register Number: 18941013532-08

~~Agencies of the European Union, including the European Commission, the European Parliament, the European Court of Justice, the European Court of Auditors, the European Central Bank, the European Investment Bank, the European Development Cooperation Office, the European External Action Service, the European Health and Consumer Agency, the European Medicines Agency, the European Environment Agency, the European Food Safety Authority, the European Agency for Safety and Health at Work, the European Agency for the Environment and the European Agency for the Reconstruction of the Balkans.~~

On 29 May 2017 at 14:40, [REDACTED] wrote:

Thanks a lot in advance [REDACTED].

Best regards,

[REDACTED]

From: [REDACTED]

Sent: Monday, May 29, 2017 2:39 PM

To: [REDACTED]


Cc: [REDACTED]

Subject: Re: Update on study

Dear [REDACTED],

Will send you the names by tomorrow COB. Thanks a lot for your patience & cooperation.

All the best,



European Public Health Alliance (EPHA) www.eph.org



Rue de Trèves 49-51 1040 Brussels (B) | Transparency Register Number: 18941013532-08

EPHA is a non-profit organization registered in Belgium. It is a member of the European Association of Public Health (EAPH) and the European Association of Public Health (EAPH). EP

On 26 May 2017 at 15:12, [REDACTED] wrote:

Dear [REDACTED],

Following our telephone conversation on 18 May, I am writing to ask whether it would be possible for you to send us a short-list of experts you would recommend to be interviewed for the study. It would be very helpful to have your “top-3” and “top-5” names from the list you have already provided (or additional ones), taking into account that they are already representatives from WHO and that we would particularly welcome the name of one or 2 experts in orphan medicines (as [REDACTED] mentioned, some experts with a practical insight would be useful, not only theoretical approaches).

Thank you so much in advance and have a nice, sunny WE!

Best regards,



From: [REDACTED]
Sent: Wednesday, May 17, 2017 7:18 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: Update on study

Dear [REDACTED],

Please call me at the [REDACTED].

Thank you,



European Commission
Health and Food Safety Directorate General (SANTE)
Unit B5 Medicines-policy, authorisation and monitoring



B-1049 Brussels, Belgium



Please consider the environment before printing this e-mail


The views expressed are purely those of the writer and may not in any circumstances be regarded as stating an official position of the European Commission. This message may contain personal and other confidential data that are entrusted to the recipients specified in the header of the message.

From: [REDACTED]
Sent: Wednesday, May 17, 2017 5:07 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: Re: Update on study

15:15 tomorrow would be great for me. Please see my numbers below or feel free to suggest a number where I can reach you.

Thank you very much once again for your time,

[REDACTED]



[REDACTED]
[REDACTED]

European Public Health Alliance (EPHA) www.ephah.org



Rue de Trèves 49-51 1040 Brussels (B) | Transparency Register Number: 18941013532-08

EPHA is a non-profit organization registered in Belgium. It is a member of the European Association of Public Health Organizations (EAPHO) and the European Public Health Alliance (EPHA). EPHE is a non-profit organization registered in Belgium. It is a member of the European Association of Public Health Organizations (EAPHO) and the European Public Health Alliance (EPHA).




On 17 May 2017 at 15:43, [REDACTED] wrote:

I have a meeting starting at 9 until 10.

In the afternoon it would be also possible, e.g. 3 pm.

Best,




From: 
Sent: Wednesday, May 17, 2017 2:53 PM
To: 
Cc: 
Subject: Re: Update on study

Hi ,

I am afraid I will be in a meeting starting at 10 am tomorrow. Would it be possible to talk around 09:30?

Thank you,







European Public Health Alliance (EPHA) www.ephah.org



Rue de Trèves 49-51 1040 Brussels (B) | Transparency Register Number: 18941013532-08

On 17 May 2017 at 11:12, [REDACTED] wrote:

Kalimera [REDACTED],

I would be available for a phone call discussion tomorrow at 10.30 before another meeting at 11:00.

Is that ok with you?

Best regards,

[REDACTED]

From: [REDACTED]
Sent: Wednesday, May 17, 2017 9:04 AM
To: [REDACTED]
Subject: Update on study


Kalimera [REDACTED],

Shall we have a phone chat/in person meeting to discuss the incentives review study?

I am available this week for a phone chat or the week of June 12 for a face to face meeting.

Se eycharistw poly! Enjoy this HOT day,

[REDACTED]





European Public Health Alliance (EPHA) www.ephah.org



Rue de Trèves 49-51 1040 Brussels (B) | Transparency Register Number: 18941013532-08

EPHA (EUROPEAN PUBLIC HEALTH ALLIANCE) is a non-profit organisation established in 2002. It is a member of the European Association of Public Health (EAPH) and the European Public Health Alliance (EPHA) is a member of the European Association of Public Health (EAPH) and the European Public Health Alliance (EPHA) is a member of the European Association of Public Health (EAPH).